Following on from the foregoing, in our study, we found that pA1c-treated groups presented lower hepatic steatosis and also lower Fasn expression that the two groups treated with metformin, even though Srebp, a major transcriptional regulator in DNL, was not significantly changed by any treatment [43]. The gene discussed is FASN; the disease is fatty liver disease.